S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:OPRX

OptimizeRx (OPRX) Stock Price, News & Analysis

$12.15
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$11.65
$12.40
50-Day Range
$11.47
$16.17
52-Week Range
$6.92
$16.65
Volume
419,135 shs
Average Volume
145,741 shs
Market Capitalization
$220.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

OptimizeRx MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
31.7% Upside
$16.00 Price Target
Short Interest
Healthy
4.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.38mentions of OptimizeRx in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$60,760 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.66) to ($0.59) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.38 out of 5 stars

Computer And Technology Sector

374th out of 588 stocks

Business Services, Not Elsewhere Classified Industry

62nd out of 90 stocks

OPRX stock logo

About OptimizeRx Stock (NASDAQ:OPRX)

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow. The company also offers Social Network Banner Messaging solution to deliver banner messaging to HCPs within their social network apps; Institutional Account-based Banner Messaging solution that provides its clients access to delivering banner messaging online and on the intranets of targeted health system accounts; and Financial Messaging solution, which provides prescribers visibility to branded copay offers and other patient support programs directly within their electronic health record and/or e-Prescribe systems. In addition, it provides Patient Engagement, a technology solution that provides digital messaging services through its cloud-based Mobile Health Messenger platform; HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance; and Therapy Initiation Workflow, a group of digital solutions that focuses on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was founded in 2006 and is headquartered in Rochester, Michigan.

OPRX Stock Price History

OPRX Stock News Headlines

Q4 2023 OPTIMIZERx Corp Earnings Call
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
OptimizeRx Q4 revenue $28.4M
OptimizeRx Q4 2023 Earnings Preview
7OPRX : OptimizeRx Earnings Preview
OptimizeRx (OPRX) to Release Earnings on Thursday
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
OptimizeRx to Participate in Upcoming Investor Conferences
OptimizeRx initiated with neutral view at Barclays
Should You Exit OptimizeRx Corp. (OPRX)?
See More Headlines
Receive OPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:OPRX
Employees
109
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$20.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+31.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-11,440,000.00
Pretax Margin
-21.88%

Debt

Sales & Book Value

Annual Sales
$62.45 million
Book Value
$7.35 per share

Miscellaneous

Free Float
17,353,000
Market Cap
$220.52 million
Optionable
Optionable
Beta
1.01
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. William J. FebboMr. William J. Febbo (Age 55)
    CEO & Director
    Comp: $694.4k
  • Mr. Stephen L. SilvestroMr. Stephen L. Silvestro (Age 46)
    President
    Comp: $458.6k
  • Mr. Edward Stelmakh C.M.A. (Age 58)
    M.B.A., CFO & COO
    Comp: $547.05k
  • Mr. Andrew Jacob D'Silva
    Senior Vice President of Corporate Finance
  • Mr. Todd Inman (Age 68)
    Chief Technology Officer
  • Ms. Marion K Odence-Ford (Age 59)
    General Counsel & Chief Compliance Officer
    Comp: $428.12k
  • Maira Alejandra
    Media Relations Manager
  • Ms. Sheryl Kearney
    Human Resources Manager
  • Mr. Terence J. Hamilton (Age 59)
    Senior Vice President of Pharma
    Comp: $441.63k
  • Dr. Doug Besch (Age 42)
    Chief Product Officer

OPRX Stock Analysis - Frequently Asked Questions

Should I buy or sell OptimizeRx stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" OPRX shares.
View OPRX analyst ratings
or view top-rated stocks.

What is OptimizeRx's stock price target for 2024?

6 Wall Street research analysts have issued 1 year price objectives for OptimizeRx's stock. Their OPRX share price targets range from $13.00 to $20.00. On average, they anticipate the company's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 31.7% from the stock's current price.
View analysts price targets for OPRX
or view top-rated stocks among Wall Street analysts.

How have OPRX shares performed in 2024?

OptimizeRx's stock was trading at $14.31 at the beginning of 2024. Since then, OPRX stock has decreased by 15.1% and is now trading at $12.15.
View the best growth stocks for 2024 here
.

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) posted its quarterly earnings results on Tuesday, November, 9th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.13 by $0.04. The business had revenue of $16.13 million for the quarter, compared to the consensus estimate of $14.82 million. OptimizeRx had a negative net margin of 21.88% and a negative trailing twelve-month return on equity of 9.24%. During the same quarter in the prior year, the business posted ($0.01) earnings per share.

What ETFs hold OptimizeRx's stock?

ETFs with the largest weight of OptimizeRx (NASDAQ:OPRX) stock in their portfolio include Jacob Forward ETF (JFWD).Global X Telemedicine & Digital Health ETF (EDOC).

What guidance has OptimizeRx issued on next quarter's earnings?

OptimizeRx issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $100.0 million-, compared to the consensus revenue estimate of $110.4 million.

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).

Who are OptimizeRx's major shareholders?

OptimizeRx's stock is owned by many different retail and institutional investors. Top institutional investors include First Light Asset Management LLC (9.52%), Vanguard Group Inc. (5.63%), Vanguard Group Inc. (5.63%), G2 Investment Partners Management LLC (2.58%), Dimensional Fund Advisors LP (1.41%) and Federated Hermes Inc. (1.01%). Insiders that own company stock include Douglas P Baker, Douglas P Baker, Edward Stelmakh, Ellen O'connor Vos, James Paul Lang, Marion Odence-Ford, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo.
View institutional ownership trends
.

How do I buy shares of OptimizeRx?

Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OPRX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners